Navigation Links
Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
Date:10/23/2007

CALGARY, Oct. 23 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. ("Oncolytics") (TSX:ONC, NASDAQ:ONCY) announced today that it has received a letter of approval from the U.K. Medicines and Healthcare products Regulatory Agency (MHRA) for its Clinical Trial Application (CTA) to begin a clinical trial using intravenous administration of REOLYSIN(R) in combination with cyclophosphamide, a chemotherapeutic agent as well as immune modulator, in patients with advanced cancers. The Principal Investigators are Dr. James Spicer of King's College in London, Dr. Johann de Bono and Dr. Kevin Harrington of The Royal Marsden NHS Foundation Trust and The Institute of Cancer Research, London, and Professor Hardev Pandha of the Royal Surrey County Hospital NHS Trust, Surrey and Mount Alvernia Hospitals.

The Company also intends to host a conference call Wednesday, October 24, 2007 to provide an update on its expanding clinical program. The dial-in details appear below.

"We are really looking forward to treating patients in this trial," said Principal Investigator Dr. James Spicer. "The hope is that it will provide valuable information about the relationship between oncolytic viral therapy and the immune response of the patient."

The trial (REO 012) is an open-label, dose-escalating, non-randomized trial of REOLYSIN(R) given intravenously with escalating doses of cyclophosphamide. A standard dose of REOLYSIN(R) is administered intravenously over five consecutive days, while an intravenous dose of cyclophosphamide is administered three days before REOLYSIN(R) treatment and continues through the course of the treatment cycle. The total number of patients studied will depend on the number of dose levels tested, but it is anticipated to be approximately 30 patients.

Eligible patients include those who have been diagnosed with advanced or metastatic solid tumours including pancreatic, lung and ovarian cancers that are refractory (have not responded) to stan
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. The state of global biotech: An Ernst & Young perspective
2. Olympics of biotechnology has international flavor
3. Biotech officials praise focus of new venture fund
4. Getting noticed in Genetown: Wisconsin biotech on display
5. Madison biotech NimbleGen files for IPO; one of states best-funded firms
6. Wisconsin biotech firm receives $107K NIH grant
7. Biotech executive books a career flight thats closer to home
8. Manufacturing partnership will move into biotech and biomedical spaces
9. Wisconsin wont get Georgia biotech without a fight
10. The 10 biggest events shaping biotech in 2006
11. Gala Biotech among companies sold for $3.3 billion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... (PRWEB) March 05, 2015 Bi-Biomics ... Histology’s paraffin and stain additive. The improvement in ... the binary features present in all daughter cells. ... protocol, chromatin packaging was analyzed at 1000-1600x using ... that chromatin patterning in all daughter cells displayed ...
(Date:3/5/2015)... TORONTO , March 5, 2015 /PRNewswire/ ... company developing new therapeutics and molecular diagnostics that target ... William G. Rice , Ph.D., Chairman, President and Chief ... ROTH Conference on Tuesday, March 10 th at ... Laguna Niguel, CA. Dr. Rice will ...
(Date:3/5/2015)... , Mar. 05, 2015 Research and Markets ... of the "Mature Biotech Outlook 2015: New Therapy ... their offering. All biotech companies - ... (CELG), in past year, have given a positive return ... companies have been able to select therapy/niche indication where ...
(Date:3/5/2015)... Chardon, Ohio (PRWEB) March 05, 2015 ... and Gold Development Partner located in Northeast Ohio, today ... chosen e2b teknologies to support its upgrade to the ... As the largest independent group practice of its kind ... base and large volume of transactions, so efficiency and ...
Breaking Biology Technology:Aptose Biosciences to Present at the 27th Annual ROTH Conference 2Aptose Biosciences to Present at the 27th Annual ROTH Conference 3Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 2Mature Biotech Outlook 2015: New Therapy Ventures Pave the Way for Success 3Physician Group Practice Chooses e2b teknologies to Support Its Upgrade to Sage 100 ERP 2014 2
... and Applied Science at Northwestern University have developed, characterized, ... atomic force microscopy (AFM), which images, measures, and manipulates ... made a much more durable probe than the commercially ... AFM to gather information from a material, but can ...
... , SEATTLE, Nov. 11 /PRNewswire-FirstCall/ - Oncothyreon Inc. (NASDAQ: ... nine months ended September 30, 2009 and provided a product ... 4:30 p.m. ET, 1:30 p.m. PT (see below for details). ... for the three months ended September 30, 2009, compared with ...
... from the electronics industry due to the drive for ... operation of these future devices, and a wide array ... of these nanowires. New research from North Carolina State ... than their larger counterparts, a finding that could pave ...
Cached Biology Technology:New nanocrystalline diamond probes overcome wear 2Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 2Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 3Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 4Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 5Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 6Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 7Oncothyreon reports third quarter 2009 financial results & provides product pipeline update 8Understanding mechanical properties of silicon nanowires paves way for nanodevices 2
(Date:2/24/2015)... 2015 This report analyzes the worldwide markets for ... analytics for the US, Canada , ... Asia-Pacific , Middle East , ... forecasts are provided for the period 2013 through 2020. Also, ... data and analytics are derived from primary and secondary research. ...
(Date:2/23/2015)... Feb. 23, 2015 NXT-ID, Inc. (NASDAQ: ... a biometric authentication company focused on the growing mobile ... patent 62114357 for DISTRIBUTED VOICE DIRECTED PAYMENT ... introduces a new groundbreaking payment method. Payment accounts may ... may only be accessed if both the speech (the ...
(Date:2/13/2015)... Feb. 13, 2015 ACT Genomics Co., ... aims to transform cancer genomic information into precision ... company has raised US$ 8 million in the its ... Taipei, Taiwan , ACT Genomics ... With the aim to implement next generation sequencing ...
Breaking Biology News(10 mins):World Iris Biometrics Industry 2World Iris Biometrics Industry 3World Iris Biometrics Industry 4World Iris Biometrics Industry 5World Iris Biometrics Industry 6World Iris Biometrics Industry 7World Iris Biometrics Industry 8World Iris Biometrics Industry 9World Iris Biometrics Industry 10World Iris Biometrics Industry 11NXT-ID Patents Voice Directed Payments 2NXT-ID Patents Voice Directed Payments 3ACT Genomics Raises $8 Million in its First Private Funding Round 2
... might go from green to white, alerting you to a ... The stuff of science fiction you say? ... research is funded in part by Homeland Security,s Science and ... Advanced Research Projects Agency (DARPA), the Office of Naval Research ...
... The Alfred P. Sloan Foundation is pleased to announce ... the prestigious Sloan Research Fellowships for 2011.,Awarded annually since ... scholars in recognition of achievement and the potential to ... colleges and universities in the U.S. and Canada, this ...
... 2011 A study by scientists at the University of ... a new way to estimate how much of the ocean,s ... help improve scientific understanding of how toxic airborne chemicals, from ... are impacting the oceans globally. By measuring Beryllium-7 ...
Cached Biology News:Sentries in the garden shed 2Sentries in the garden shed 3University of Miami scientists find new way to estimate global rainfall and track ocean pollution 2
G-protein coupled purinergic receptor P2Y8...
Phospho-FAK (Tyr576/577) Antibody...
Zinc finger MYM-type protein 3 (Zinc finger protein 261) (DXS6673E protein). [Source:Uniprot/SWISSPROT;Acc:Q14202] Antigen: Recombinant Protein Epitope Signature Tag (PrEST)....
Rabbit polyclonal to Leucyl tRNA synthetase ( Abpromise for all tested applications). Antigen: L930-H1176 denatured human recombinant LRS. Entrez Gene ID: 3926 Swiss Protein ID: Q9P2J5...
Biology Products: